Encision (ECIA) 10-Q 12 Aug 22 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--03-31
Entity File Number	001-11789
Entity Registrant Name	ENCISION INC.
Entity Central Index Key	0000930775
Entity Tax Identification Number	84-1162056
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	6797 Winchester Circle
Entity Address, City or Town	Boulder
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80301
City Area Code	(303)
Local Phone Number	444-2600
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	ECIA
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		11,719,543

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Current assets:
Cash	$ 827,944	$ 949,645
Accounts receivable	921,123	947,623
Inventories, net of reserve for obsolescence of $34,948 at June 30, 2022 and $36,000 at March 31, 2022	1,798,655	1,584,321
Prepaid expenses and other assets	101,287	120,133
Total current assets	3,649,009	3,601,722
Equipment:
Furniture, fixtures and equipment, at cost	2,499,871	2,468,949
Accumulated depreciation	(2,265,202)	(2,279,652)
Equipment, net	234,669	189,297
Right of use asset	715,349	786,407
Patents, net of accumulated amortization of $290,077 at June 30, 2022 and $282,081 at March 31, 2022	177,589	180,719
Other assets	42,198	34,240
TOTAL ASSETS	4,818,814	4,792,385
Current liabilities:
Accounts payable	388,077	576,381
Secured notes	23,154	21,491
Accrued compensation	221,678	190,853
Other accrued liabilities	114,835	125,179
Accrued lease liability	370,677	362,487
Total current liabilities	1,118,421	1,276,391
Long-term liability:
Secured notes	200,806	205,809
Accrued lease liability	476,761	564,321
Total liabilities	1,795,988	2,046,521
Shareholders’ equity:
Preferred stock, no par value: 10,000,000 shares authorized; none issued and outstanding
Common stock and additional paid-in capital, no par value: 100,000,000 shares authorized; 11,719,543 issued and outstanding at June 30, 2022 and March 31, 2022	24,287,544	24,275,183
Accumulated (deficit)	(21,264,718)	(21,529,319)
Total shareholders’ equity	3,022,826	2,745,864
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 4,818,814	$ 4,792,385

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Statement of Financial Position [Abstract]
Inventories, reserve for obsolescence	$ 34,948	$ 36,000
Accumulated amortization	$ 290,077	$ 282,081
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0	$ 0
Common stock and additional paid-in capital, shares authorized	100,000,000	100,000,000
Common stock and additional paid-in capital, shares issued	11,719,543	11,719,543
Common stock and additional paid-in capital, shares outstanding	11,719,543	11,719,543

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
NET REVENUE:
Total revenue	$ 2,154,362	$ 2,008,444
COST OF REVENUE:
Total cost of revenue	869,905	981,476
GROSS PROFIT	1,284,457	1,026,968
OPERATING EXPENSES:
Sales and marketing	502,967	528,474
General and administrative	344,119	326,721
Research and development	170,469	176,875
Total operating expenses	1,017,555	1,032,070
OPERATING (LOSS) INCOME	266,902	(5,102)
Interest expense, net	(2,363)	(1,806)
Other income (expense), net	61	66
Interest expense, extinguishment of debt income and other income (expense), net	(2,302)	(1,740)
(LOSS) INCOME BEFORE PROVISION FOR INCOME TAXES	264,601	(6,842)
Provision for income taxes
NET (LOSS) INCOME	$ 264,601	$ (6,842)
Net (loss) income per share—basic and diluted	$ 0.02	$ 0
Weighted average shares—basic	11,719,543	11,582,641
Weighted average shares—diluted	12,021,280	11,582,641
Product [Member]
NET REVENUE:
Total revenue	$ 1,696,029	$ 1,718,404
COST OF REVENUE:
Total cost of revenue	869,905	838,426
GROSS PROFIT	826,124	879,978
OPERATING EXPENSES:
OPERATING (LOSS) INCOME	(191,431)	(152,092)
Service [Member]
NET REVENUE:
Total revenue	458,333	290,040
COST OF REVENUE:
Total cost of revenue		143,050
GROSS PROFIT	458,333	146,990
OPERATING EXPENSES:
OPERATING (LOSS) INCOME	$ 458,333	$ 146,990

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows (used in) operating activities:
Net income	$ 264,601	$ (6,842)
Adjustments to reconcile net income to net cash (used in) operating activities:
Depreciation and amortization	20,087	26,783
Stock-based compensation expense related to stock options	12,361	8,340
(Recovery from) doubtful accounts, net change		(25,000)
(Recovery from) provision for inventory obsolescence, net change	(1,052)	(49,000)
Change in operating assets and liabilities:
Right of use asset, net	(8,312)	(4,687)
Accounts receivable	26,500	(91,601)
Inventories	(213,282)	(96,813)
Prepaid expenses and other assets	10,888	44,049
Accounts payable	(188,304)	131,938
Accrued compensation and other accrued liabilities	20,481	(65,216)
Net cash (used in) generated by operating activities	(56,032)	(128,049)
Cash flows (used in) investing activities:
Acquisition of property and equipment	(57,463)	(6,720)
Patent costs	(4,866)	(7,561)
Net cash (used in) generated by investing activities	(62,329)	(14,281)
Cash flows from financing activities:
(Paydown of) secured notes	(3,340)	(3,340)
Net cash (used in) generated by financing activities	(3,340)	(3,340)
Net (decrease) increase in cash	(121,701)	(145,670)
Cash, beginning of fiscal year	949,645	1,474,339
Cash, end of fiscal quarter	827,944	1,328,669
Supplemental disclosures of cash flow information:
Cash paid during the three months for interest	$ 2,363	$ 1,806

ORGANIZATION AND NATURE OF BUSI

ORGANIZATION AND NATURE OF BUSINESS	3 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND NATURE OF BUSINESS	Note 1. ORGANIZATION AND NATURE OF BUSINESS Encision Inc. is a medical device company that designs, develops, manufactures and markets patented surgical instruments that provide greater safety to, and saves lives of, patients undergoing minimally-invasive surgery. We believe that our patented AEM ® We have an accumulated deficit of $ 21,264,718 264,601 12,361 Our strategic marketing and sales plan is designed to expand the use of our products in surgically active hospitals and surgery centers in the United States. We have been actively monitoring the coronavirus (“COVID”) situation and its impact globally. Our production facilities continued to operate during the year as they had prior to the COVID pandemic with minimal change, other than for enhanced safety measures intended to prevent the spread of the virus. The remote working arrangements and travel restrictions imposed by various governments had limited impact on our ability to maintain operations during the year, as our manufacturing operations have generally been exempted from stay-at-home orders. However, we cannot predict the impact of the progression of the COVID pandemic on future results due to a variety of factors, including the continued good health of our employees, the ability of suppliers to continue to operate and deliver, our ability and our customers to maintain operations, continued access to transportation resources, the changing needs and priorities of customers, any further government and/or public actions taken in response to the pandemic and ultimately the length of the pandemic. We will continue to closely monitor the COVID pandemic in order to ensure the safety of our people and our ability to serve our customers and patients worldwide.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with GAAP. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year. Use of Estimates in the Preparation of Financial Statements Cash and Cash Equivalents Fair Value of Financial Instruments Concentration of Credit Risk 250,000 We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at June 30, 2022 of $ 921,123 947,623 Inventories Schedule of inventory June 30, 2022 March 31, 2022 Raw materials $ 1,318,891 $ 1,083,387 Finished goods 514,712 536,934 Total gross inventories 1,833,603 1,620,321 Less reserve for obsolescence (34,948 ) (36,000 ) Total net inventories $ 1,798,655 $ 1,584,321 Property and Equipment 12,091 14,877 Long-Lived Assets Patents Income Taxes no no Revenue Recognition Research and Development Expenses Stock-Based Compensation Stock-based compensation expense recognized under ASC 718 for the three months ended June 30, 2022 and 2021 was $ 12,361 8,340 Segment Reporting Schedule of service performs electrical engineering activities for external entities Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Product Service Total Product Service Total Net revenue $ 1,696,029 $ 458,333 $ 2,154,362 $ 1,718,404 $ 290,040 $ 2,008,444 Cost of revenue 869,905 — 869,905 838,426 143,050 981,476 Gross profit 826,124 458,333 1,284,457 879,978 146,990 1,026,968 Operating income (loss) (191,431 ) 458,333 266,902 (152,092 ) 146,990 (5,102 ) Depreciation and amortization 20,087 — 20,087 26,783 — 26,783 Patent and capital expenditures 62,329 — 62,329 14,281 — 14,281 Equipment and patents, net $ 412,258 $ — $ 412,258 $ 370,016 $ — $ 370,016 Recently Issued Accounting Pronouncements

Basic and Diluted Income and Lo

Basic and Diluted Income and Loss per Common Share	3 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Basic and Diluted Income and Loss per Common Share	Note 3. Basic and Diluted Income and Loss per Common Share We report both basic and diluted net income (loss) per share. Basic net income or loss per common share is computed by dividing net income or loss for the period by the weighted average number of common shares outstanding for the period. Diluted net income or loss per common share is computed by dividing the net income or loss for the period by the weighted average number of common and potential common shares outstanding during the period if the effect of the potential common shares is dilutive. The shares used in the calculation of dilutive potential common shares exclude options to purchase shares where the exercise price was greater than the average market price of common shares for the period. The following table presents the calculation of basic and diluted net income (loss) per share: Schedule of basic and diluted net loss per share Three Months Ended June 30, 2022 June 30, 2021 Net (loss) income $ 264,601 $ (6,842 ) Weighted-average basic shares outstanding 11,719,543 11,582,641 Effect of dilutive securities 301,737 — Weighted-average diluted shares 12,021,280 11,582,641 Basic net income (loss) per share $ 0.02 $ 0.00 Diluted net income (loss) per share $ 0.02 $ 0.00 Antidilutive employee stock options 756,263 1,036,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 4. COMMITMENTS AND CONTINGENCIES We have a noncancelable lease agreement for our facilities at 6797 Winchester Circle, Boulder, Colorado. The lease expires October 31, 2024. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) ("ASU 2016-02"), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as either finance or operating leases under previous accounting standards and disclosing key information about leasing arrangements. We adopted Topic 842 on April 1, 2019, using the alternative modified transition method, which requires a cumulative effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. There was no cumulative effect adjustment recorded on April 1, 2019. The primary impact for us was the balance sheet recognition of right-of-use (“ROU”) assets and lease liabilities for operating leases as a lessee. We determine if an arrangement contains a lease at inception. We currently do not have any finance leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. We use our incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities as our leases do not provide an implicit rate. Lease expense is recognized on a straight-line basis over the lease term. The minimum future lease payment, by fiscal year, as of June 30, 2022 is as follows: Schedule of Lease payment Fiscal Year Amount 2023 $ 281,542 2024 386,667 2025 232,139 Total $ 900,348 During January 2021, we canceled our relationship with Crestmark Bank. We had no borrowings and incurred a $20,000 exit fee. On August 4, 2020, we received $ 150,000 150,000 3.75 August 1, 2050 During January 2021, we entered into a note agreement with U.S. Bank for $92,000. The note is for five years at a 5% interest rate and the proceeds were used to purchase equipment. The note is secured by the equipment. On April 17, 2020, we entered into an unsecured promissory note under the PPP for a principal amount of $ 598,567 598,567 598,567 533,118 533,118 The minimum future EIDL payment, by fiscal year, as of June 30, 2022 is as follows: Schedule of EIDL payment Fiscal Year Amount 2023 $ 1,546 2024 3,208 2025 3,331 2026 3,457 Thereafter 148,018 Total $ 159,560 During January 2021, we entered into a note agreement with U.S. Bank for $92,000. The note is for five years at a 5% interest rate and the proceeds were used to purchase equipment. The note is secured by the equipment. The minimum future principal U.S. Bank payment, by fiscal year, as of June 30, 2022 is as follows: Schedule of principal U.S. Bank payment Fiscal Year Amount 2023 $ 13,800 2024 18,400 2025 18,400 2026 13,800 Total $ 64,400 Aside from the operating lease, EIDL loan and U.S. Bank loan, we do not have any material contractual commitments requiring settlement in the future. We are subject to regulation by the United States Food and Drug Administration (“FDA”). The FDA provides regulations governing the manufacture and sale of our products and regularly inspects us and other manufacturers to determine compliance with these regulations. We believe that we were in substantial compliance with all known regulations at June 30, 2022. FDA inspections are conducted periodically at the discretion of the FDA. Our latest inspection by the FDA occurred in October 2019.

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	3 Months Ended
	Jun. 30, 2022
Equity [Abstract]
SHARE-BASED COMPENSATION	Note 5. SHARE-BASED COMPENSATION The provisions of ASC 718-10-55 requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors, including employee stock options and RSUs, based on estimated fair values. The following table summarizes stock-based compensation expense related to employee stock options for the three months ended June 30, 2022 and 2021, which was allocated as follows: Schedule of summarizes stock-based compensation Three Months Ended June 30, 2022 June 30, 2021 Cost of sales $ 158 $ 918 Sales and marketing 1,656 1,218 General and administrative 9,429 5,658 Research and development 1,118 546 Stock-based compensation expense $ 12,361 $ 8,340 Share-based compensation cost for stock options is measured at the grant date, based on the fair value as calculated by the Black-Scholes-Merton ("BSM") option-pricing model. The BSM option-pricing model requires the use of actual employee exercise behavior data and the application of a number of assumptions, including expected volatility, risk-free interest rate and expected dividends. There were no As of June 30, 2022, approximately $ 182,000

RELATED PARTY TRANSACTION

RELATED PARTY TRANSACTION	3 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	Note 6. RELATED PARTY TRANSACTION We paid consulting fees of $ 13,728 28,816

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 7. SUBSEQUENT EVENTS We evaluated all of our activity as of the date the condensed interim financial statements were issued and concluded that no subsequent events have occurred that would require recognition in our financial statements or disclosed in the notes to our condensed interim financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed interim financial statements have been prepared, in all material respects, in conformity with the standards of accounting measurements and reflect, in the opinion of management, all adjustments necessary to summarize fairly the financial position and results of operations for such periods in accordance with GAAP. All adjustments are of a normal recurring nature. The results of operations for the most recent interim period are not necessarily indicative of the results to be expected for the full year.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements
Cash and Cash Equivalents	Cash and Cash Equivalents
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Concentration of Credit Risk	Concentration of Credit Risk 250,000 We have no significant off-balance sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. We maintain the majority of our cash balances with one financial institution in the form of demand deposits. Accounts receivable are typically unsecured and are derived from transactions with and from entities in the healthcare industry primarily located in the United States. Accordingly, we may be exposed to credit risk generally associated with the healthcare industry. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. The net accounts receivable balance at June 30, 2022 of $ 921,123 947,623
Inventories	Inventories Schedule of inventory June 30, 2022 March 31, 2022 Raw materials $ 1,318,891 $ 1,083,387 Finished goods 514,712 536,934 Total gross inventories 1,833,603 1,620,321 Less reserve for obsolescence (34,948 ) (36,000 ) Total net inventories $ 1,798,655 $ 1,584,321
Property and Equipment	Property and Equipment 12,091 14,877
Long-Lived Assets	Long-Lived Assets
Patents	Patents
Income Taxes	Income Taxes no no
Revenue Recognition	Revenue Recognition
Research and Development Expenses	Research and Development Expenses
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense recognized under ASC 718 for the three months ended June 30, 2022 and 2021 was $ 12,361 8,340
Segment Reporting	Segment Reporting Schedule of service performs electrical engineering activities for external entities Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Product Service Total Product Service Total Net revenue $ 1,696,029 $ 458,333 $ 2,154,362 $ 1,718,404 $ 290,040 $ 2,008,444 Cost of revenue 869,905 — 869,905 838,426 143,050 981,476 Gross profit 826,124 458,333 1,284,457 879,978 146,990 1,026,968 Operating income (loss) (191,431 ) 458,333 266,902 (152,092 ) 146,990 (5,102 ) Depreciation and amortization 20,087 — 20,087 26,783 — 26,783 Patent and capital expenditures 62,329 — 62,329 14,281 — 14,281 Equipment and patents, net $ 412,258 $ — $ 412,258 $ 370,016 $ — $ 370,016
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Schedule of inventory	Schedule of inventory June 30, 2022 March 31, 2022 Raw materials $ 1,318,891 $ 1,083,387 Finished goods 514,712 536,934 Total gross inventories 1,833,603 1,620,321 Less reserve for obsolescence (34,948 ) (36,000 ) Total net inventories $ 1,798,655 $ 1,584,321
Schedule of service performs electrical engineering activities for external entities	Schedule of service performs electrical engineering activities for external entities Three Months Ended June 30, 2022 Three Months Ended June 30, 2021 Product Service Total Product Service Total Net revenue $ 1,696,029 $ 458,333 $ 2,154,362 $ 1,718,404 $ 290,040 $ 2,008,444 Cost of revenue 869,905 — 869,905 838,426 143,050 981,476 Gross profit 826,124 458,333 1,284,457 879,978 146,990 1,026,968 Operating income (loss) (191,431 ) 458,333 266,902 (152,092 ) 146,990 (5,102 ) Depreciation and amortization 20,087 — 20,087 26,783 — 26,783 Patent and capital expenditures 62,329 — 62,329 14,281 — 14,281 Equipment and patents, net $ 412,258 $ — $ 412,258 $ 370,016 $ — $ 370,016

Basic and Diluted Income and _2

Basic and Diluted Income and Loss per Common Share (Tables)	3 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share	Schedule of basic and diluted net loss per share Three Months Ended June 30, 2022 June 30, 2021 Net (loss) income $ 264,601 $ (6,842 ) Weighted-average basic shares outstanding 11,719,543 11,582,641 Effect of dilutive securities 301,737 — Weighted-average diluted shares 12,021,280 11,582,641 Basic net income (loss) per share $ 0.02 $ 0.00 Diluted net income (loss) per share $ 0.02 $ 0.00 Antidilutive employee stock options 756,263 1,036,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Jun. 30, 2022
Lease Payment [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of principal U.S. Bank payment	Schedule of Lease payment Fiscal Year Amount 2023 $ 281,542 2024 386,667 2025 232,139 Total $ 900,348
E I D L Payment [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of principal U.S. Bank payment	Schedule of EIDL payment Fiscal Year Amount 2023 $ 1,546 2024 3,208 2025 3,331 2026 3,457 Thereafter 148,018 Total $ 159,560
U S Bank Payment [Member]
Defined Benefit Plan Disclosure [Line Items]
Schedule of principal U.S. Bank payment	Schedule of principal U.S. Bank payment Fiscal Year Amount 2023 $ 13,800 2024 18,400 2025 18,400 2026 13,800 Total $ 64,400

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of summarizes stock-based compensation	Schedule of summarizes stock-based compensation Three Months Ended June 30, 2022 June 30, 2021 Cost of sales $ 158 $ 918 Sales and marketing 1,656 1,218 General and administrative 9,429 5,658 Research and development 1,118 546 Stock-based compensation expense $ 12,361 $ 8,340

ORGANIZATION AND NATURE OF BU_2

ORGANIZATION AND NATURE OF BUSINESS (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 21,264,718		$ 21,529,319
Net income	264,601	$ (6,842)
Stock options exercised	$ 12,361

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Accounting Policies [Abstract]
Raw materials	$ 1,318,891	$ 1,083,387
Finished goods	514,712	536,934
Total gross inventories	1,833,603	1,620,321
Less reserve for obsolescence	(34,948)	(36,000)
Total net inventories	$ 1,798,655	$ 1,584,321

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Product Information [Line Items]
Net revenue	$ 2,154,362	$ 2,008,444
Cost of revenue	869,905	981,476
Gross profit	1,284,457	1,026,968
Operating income (loss)	266,902	(5,102)
Depreciation and amortization	20,087	26,783
Patent and capital expenditures	62,329	14,281
Equipment and patents, net	412,258	370,016
Product [Member]
Product Information [Line Items]
Net revenue	1,696,029	1,718,404
Cost of revenue	869,905	838,426
Gross profit	826,124	879,978
Operating income (loss)	(191,431)	(152,092)
Depreciation and amortization	20,087	26,783
Patent and capital expenditures	62,329	14,281
Equipment and patents, net	412,258	370,016
Service [Member]
Product Information [Line Items]
Net revenue	458,333	290,040
Cost of revenue		143,050
Gross profit	458,333	146,990
Operating income (loss)	458,333	146,990
Depreciation and amortization
Patent and capital expenditures
Equipment and patents, net

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Accounting Policies [Abstract]
Federally insured limit	$ 250,000
Accounts receivable	921,123		$ 947,623
Depreciation expense	12,091	$ 14,877
Unrecognized tax benefits	0
Uncertain tax positions	0
Stock based compensation	$ 12,361	$ 8,340

BASIC AND DILUTED INCOME AND _3

BASIC AND DILUTED INCOME AND LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Earnings Per Share [Abstract]
Net (loss) income	$ 264,601	$ (6,842)
Weighted-average basic shares outstanding	11,719,543	11,582,641
Effect of dilutive securities	301,737
Weighted-average diluted shares	12,021,280	11,582,641
Basic net income (loss) per share	$ 0.02	$ 0
Diluted net income (loss) per share	0.02	0
Antidilutive employee stock options	$ 756,263	$ 1,036,000

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - Lease Payment [Member]	Jun. 30, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
2023	$ 281,542
2024	386,667
2025	232,139
Total	$ 900,348

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 1) - E I D L Payment [Member]	Jun. 30, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
2023	$ 1,546
2024	3,208
2025	3,331
2026	3,457
Thereafter	148,018
Total	$ 159,560

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details 2) - U S Bank Payment [Member]	Jun. 30, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
2023	$ 13,800
2024	18,400
2025	18,400
2026	13,800
Total	$ 64,400

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)			1 Months Ended	3 Months Ended
	Aug. 04, 2021	Aug. 01, 2020	Dec. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Feb. 08, 2021	Apr. 17, 2020
SBA [Member]
Debt Instrument [Line Items]
Proceed from loan	$ 150,000
EIDL [Member]
Debt Instrument [Line Items]
Principal amount		$ 150,000
Interest rate		3.75%
Debt Instrument, Maturity Date		Aug. 01, 2050
PPPLoan [Member]
Debt Instrument [Line Items]
Principal amount						$ 533,118	$ 598,567
Debt Forgiveness					$ 598,567
Extinguishment of debt income			$ 598,567	$ 533,118

SHARE-BASED COMPENSATION (Detai

SHARE-BASED COMPENSATION (Details) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Stock-based compensation expense related to grants of employee stock options	$ 12,361	$ 8,340
Cost of Sales [Member]
Stock-based compensation expense related to grants of employee stock options	158	918
Selling and Marketing Expense [Member]
Stock-based compensation expense related to grants of employee stock options	1,656	1,218
General and Administrative Expense [Member]
Stock-based compensation expense related to grants of employee stock options	9,429	5,658
Research and Development Expense [Member]
Stock-based compensation expense related to grants of employee stock options	$ 1,118	$ 546

SHARE-BASED COMPENSATION (Det_2

SHARE-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Stock options granted	0	0
Number of shares exercised	0	0
Stock options forfeited	0	0
Unrecognized compensation costs	$ 182,000

RELATED PARTY TRANSACTION (Deta

RELATED PARTY TRANSACTION (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Director [Member]
Related Party Transaction [Line Items]
Consulting fees paid	$ 13,728	$ 28,816